An original investigation published in JAMA Ophthalmology indicated that the megablockbuster metabolic medication Wegovy (semaglutide) may increase the risk of a serious eye condition. The research, published on Wednesday, examined the occurrence of nonarteritic anterior ischemic optic neuropathy (NAION) in patients taking semaglutide. The GLP-1 receptor agonists Wegovy, Ozempic, and Rybelsus, all containing the active…
Could Wegovy’s cardiovascular label expansion be a catalyst for GLP-1 obesity drug coverage?
The recent FDA approval of a cardiovascular risk reduction indication for Wegovy (semaglutide) could point toward a significant opportunity for pharma companies seeking to reshape payer perceptions and expand coverage for next-gen metabolic therapies. This regulatory shift, allowing Wegovy to be prescribed for reducing the risk of major adverse cardiovascular events such as heart attack…
How Novo Nordisk’s Wegovy cardiovascular benefits could drive further growth
Semaglutide was already one of the best-selling drugs of recent memory. And Novo Nordisk the fastest-growing Big Pharma firm. Now, the FDA’s decision to expand the label of its weight-loss version of the drug to include cardiovascular benefits could help unlock more growth momentum for Novo Nordisk. This positions Wegovy as the first weight-loss medication…
Novo Nordisk achieves 74% growth surge, clinching fastest-growing pharma title
No longer just a diabetes company, Novo Nordisk’s semaglutide-based therapies have fueled its rise to pharma powerhouse status. From 2021 to 2023, the company cemented its position as the fastest-growing Big Pharma player, reaching a 35% year-over-year growth rate in 2023 and 74% growth from 2020 to 2023 when measured in U.S. dollars. While Pfizer…
An overview of the GLP-1 landscape in obesity therapeutics
The GLP-1 drug market continues to boom lately thanks to highly effective new medications like Novo Nordisk’s Wegovy and continued demand for the drug class in diabetes. The runaway success of Wegovy and Ozempic (both formulations of semaglutide) has caused Novo Nordisk’s share price to skyrocket in 2023, briefly making the Danish pharmaceutical company the most…
Semaglutide supply shortfall fuels demand for alternatives
Novo Nordisk (NYSE:NVO) continues to face supply shortages for its Wegovy (semaglutide) pens, which are FDA approved for weight management. Against that backdrop, a growing number of companies have begun selling compounded versions of the drug. Drug compounding involves “combining, mixing, or altering ingredients to create a medication tailored to the needs of an individual patient,”…